αB-crystallin expression in breast cancer is associated with brain metastasis
暂无分享,去创建一个
Charles M Perou | C. Fan | C. Perou | T. Nielsen | M. Cheang | A. Minn | K. D. Voduc | H. Kennecke | J. Harrell | V. Cryns | Torsten O Nielsen | Cheng Fan | Maggie C U Cheang | Andy J Minn | K David Voduc | J Chuck Harrell | Hagen Kennecke | Vincent L Cryns
[1] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[2] W. Gradishar,et al. ERK-regulated αB-Crystallin Induction by Matrix Detachment Inhibits Anoikis and Promotes Lung Metastasis in vivo , 2015, Oncogene.
[3] N. Lin,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.
[4] C. Miller,et al. αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain , 2013, Clinical Cancer Research.
[5] A. Stan,et al. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer , 2007, Modern Pathology.
[6] L. Chin,et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma , 2008, Proceedings of the National Academy of Sciences.
[7] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[8] E. Winer,et al. Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.
[9] Charles M. Perou,et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.
[10] Marta C Guadamillas,et al. Overcoming anoikis – pathways to anchorage-independent growth in cancer , 2011, Journal of Cell Science.
[11] K. Camphausen,et al. Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.
[12] G. Reddy,et al. Emerging role for αB-crystallin as a therapeutic agent: pros and cons. , 2015, Current molecular medicine.
[13] V. Cryns,et al. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.
[14] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Tan,et al. αB‐crystallin is a useful marker for triple negative and basal breast cancers , 2012, Histopathology.
[16] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[17] E. Winer,et al. CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Steinberg,et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.
[19] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[20] W. Gerald,et al. Genes that mediate breast cancer metastasis to the brain , 2009, Nature.
[21] A. Rademaker,et al. αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.
[22] H. Kang,et al. αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer , 2011, Journal of breast cancer.
[23] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[24] H. Harputluoglu,et al. Breast cancer subtypes and outcomes of central nervous system metastases. , 2011, Breast.
[25] Andy J. Minn,et al. Genes that mediate breast cancer metastasis to lung , 2005, Nature.
[26] J. C. Wilkinson,et al. The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* , 2005, Journal of Biological Chemistry.
[27] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[28] P. Mehlen,et al. Human hsp27, Drosophila hsp27 and human alphaB‐crystallin expression‐mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha‐induced cell death. , 1996, The EMBO journal.
[29] Joel S. Parker,et al. Adjustment of systematic microarray data biases , 2004, Bioinform..
[30] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Perou,et al. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard , 2013, Modern Pathology.
[32] G. Hortobagyi,et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[35] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[36] F. Chen,et al. The Small Heat Shock Protein αB-Crystallin Negatively Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its Autoproteolytic Maturation* , 2001, The Journal of Biological Chemistry.
[37] Lang Li,et al. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients , 2015, Journal of Neuro-Oncology.
[38] J. Moyano,et al. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. , 2008, Annals of diagnostic pathology.
[39] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] John W M Martens,et al. Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.
[41] T. Nielsen,et al. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. , 2008, Clinical breast cancer.
[42] Reddy Vs,et al. Emerging role for αB-crystallin as a therapeutic agent: pros and cons. , 2015 .